Patients are talking. Are you listening?
Every day, millions of patients share their real-world drug experiences across social media platforms, online forums, patient communities, and review sites. These conversations contain valuable adverse event signals that traditional spontaneous reporting systems never capture.
Drugvigil's Social Media Mining service systematically monitors, extracts, and evaluates potential adverse event data from digital sources — turning unstructured patient narratives into structured, actionable pharmacovigilance intelligence.
Our approach aligns with the FDA's Draft Guidance on Social Media and Internet Use and EMA's recommendations on digital data sources for signal detection. We don't replace your safety database — we expand its reach into sources your competitors are ignoring.
We mine where patients speak — not where regulators look.
Our monitoring spans across multiple digital channels where adverse events surface organically:
From raw posts to regulatory-ready case reports.
Our pipeline transforms unstructured social media content into validated pharmacovigilance data through a structured workflow:
The data gap your safety database can't fill.
Studies estimate that only 1-10% of adverse drug reactions are ever reported through traditional spontaneous reporting. Social media captures the rest — the side effects patients discuss with peers but never report to their doctor or a health authority.
Regulatory agencies are increasingly expecting Marketing Authorization Holders to demonstrate awareness of safety information circulating in digital channels. Social media mining is no longer optional — it is an emerging regulatory expectation.
With Drugvigil, you get:
Want to talk about our upcoming projects?
Copyright © Drugvigil. All Rights Reserved.